참고문헌
- Alacacioglu A, Somali I, Simsek I, et al (2008). Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol, 38, 683-8. https://doi.org/10.1093/jjco/hyn082
- Beasley RP, Hwang LY, Lin CC, et al (1981). Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet, 21, 1129-33.
- Borzio M, Colloredo G, Pioltelli P, et al (2007). Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis, 39, 1011-7. https://doi.org/10.1016/j.dld.2007.06.018
- Bosch FX, Ribes J, Borras J (1999). Epidemiology of primary liver cancer. Semin Liver Dis, 19, 271-85. https://doi.org/10.1055/s-2007-1007117
- Bruix J, Sherman M (2005). Menagement of hepatocellular carcinoma. An update. AASLD Practice Guidelines.
- Chang HC, Lin YM, Yen AMF, et al (2013). Predictors of longterm survival in hepatocellular carcinomas: a longitudinal follow-up of 108 patients with small tumors. Anticancer Res, 33, 5171-8
- Dogan E, Yalcin S, Koca D, et al (2012). Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev, 13, 2985-90. https://doi.org/10.7314/APJCP.2012.13.6.2985
- Fong Y, Sun RL, Jarnagin W, et al (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg, 229, 790-800. https://doi.org/10.1097/00000658-199906000-00005
- Geramizadeh B, Asadi N, Tabei SZ (2012). Cytologic comparison between malignant and regenerative nodules in the background of cirrhosis. Hepat Mon, 12, 448-52 https://doi.org/10.5812/hepatmon.5954
- Hassan MM, Hwang LY, Hatten CJ, et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36, 1206-13. https://doi.org/10.1053/jhep.2002.36780
- Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50. https://doi.org/10.1200/JCO.2005.05.2308
- Lee FI (1966). Cirrhosis and hepatoma in alcoholics. Gut, 7, 77-85. https://doi.org/10.1136/gut.7.1.77
- Lee CH, Hsieh SY, Lin JL et al (2013). Hepatocellular carcinoma in patients with chronic kidney disease. World J Gastroenterol ,19, 2466-72. https://doi.org/10.3748/wjg.v19.i16.2466
- Lehman EM, Wilson ML (2009). Epidemiology of hepatitis viruses among hepatocellular car cinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer, 124, 690-7. https://doi.org/10.1002/ijc.23937
- Lim HY, Sohn I, Deng S, et al (2013). Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol, 20, 3747-53. https://doi.org/10.1245/s10434-013-3070-y
- Markovic S, Gadzijev E, Stabuc B, et al (1998). Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol, 29, 650-9. https://doi.org/10.1016/S0168-8278(98)80162-1
- Marrero CR, Marrero JA (2007). Viral hepatitis and hepatocellular carcinoma. Arch Med Res, 38, 612-20. https://doi.org/10.1016/j.arcmed.2006.09.004
- Monto A, Wright TL (2001). The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol, 28, 441-9. https://doi.org/10.1016/S0093-7754(01)90137-X
- Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. https://doi.org/10.7314/APJCP.2013.14.11.6955
- Ozer B, Serin E, Yilmaz U, et el (2003). Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. Turk J Gastroenterol, 14, 85-90.
- Purtilo DT, Kersey JH, Hallgren HM, et al (1973). Alphafetoprotein: diagnostic and prognostic use in patients with hepatomas. Am J Clin Pathol, 59, 295-9.
- Sakar B, Ustuner Z, Karagol H, et al (2004). Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol, 27, 489-93. https://doi.org/10.1097/01.coc.0000136019.94333.09
- Schoniger-Hekele M, Muller C, Kutilek M, et al (2001). Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut, 48, 103-9. https://doi.org/10.1136/gut.48.1.103
- Stroffolini T, Andreone P, Andriulli A, et al (1998). Characteristics of hepatocellular carcinoma in Italy. J Hepatol, 29, 944-52. https://doi.org/10.1016/S0168-8278(98)80122-0
- Stuart KE, Anand AJ, Jenkins RL (1996). Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer, 77, 2217-22. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M
- Su CH, Lin Y, Cai L (2013). enetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 49053-60.
- Turkey Liver Research Association National Hepatitis Often Study (TURKHEP 2010).
- Wang BE, Ma WM, Sulaiman A, et al (2002). Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. J Med Virol, 67, 394-400. https://doi.org/10.1002/jmv.10087
- Yaprak O, Akyildiz M, Dayangac M, et al (2012). AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 11, 256-61. https://doi.org/10.1016/S1499-3872(12)60157-X
- Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al (2001). Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci, 46, 1022-8. https://doi.org/10.1023/A:1010705910858
- Xu J, Liu C, Zhou L, et al (2012). Distinctions between clinicopathological factors and prognosis of alphafetoprotein negative and positive hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62. https://doi.org/10.7314/APJCP.2012.13.2.559
- Yalcin K, Yakut M, Degertekin H, et al (2013). Clinical and epidemiological characteristics of hepatocellular carsinoma cases in East and Southeastern Region of Turkey. Clin J Med, 33, 806-13.
- Yeo Y, Gwack J, Kang S, et al (2013). Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac J Cancer Prev, 14, 6227-31. https://doi.org/10.7314/APJCP.2013.14.11.6227
- Zhang BH, Yang BH, Tang ZY (2004). Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol, 130, 417-22.
- Zidan A, Scheuerlein H, Schule S, et al (2012). Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in Iran and wordwide. Hepat Mon, 12, 14-22.
피인용 문헌
- Biological Screening of Novel Derivatives of Valproic Acid for Anticancer and Antiangiogenic Properties vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7785
- Retrospective Evaluation of Discrepancies between Radiological and Pathological Size of Hepatocellular Carcinoma Masses vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9487
- Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study vol.3, pp.6, 2015, https://doi.org/10.3892/mco.2015.633
- Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.473
- MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis vol.17, pp.1, 2017, https://doi.org/10.1186/s12935-017-0471-1